Docetaxel + TroVax

Phase 2Terminated
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Refractory Prostate Cancer

Conditions

Hormone Refractory Prostate Cancer

Trial Timeline

Aug 1, 2010 → Mar 1, 2013

About Docetaxel + TroVax

Docetaxel + TroVax is a phase 2 stage product being developed by Oxford Biomedica for Hormone Refractory Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01194960. Target conditions include Hormone Refractory Prostate Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01194960Phase 2Terminated